Life Science News

New Bloom location will serve as a hub on the Eastern Seaboard to provide operational health services to wide array of organizations

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for healthcare security, announces the opening of new facilities in New Jersey to allow central access to surrounding metropolitan centers such as New York City, Philadelphia, Boston and Washington, DC.

The new location provides expanded laboratories for operational health services and diagnostic testing to meet rapidly growing demand. As part of this expansion, Bloom has also added a local team. The New Jersey facility will serve Fortune 500 clients, sporting events, film/TV productions in New York and surrounding areas. The new facilities are an addition to Bloom's existing locations in Dallas, Atlanta, Montgomery, and Los Angeles.

"Our new location in New Jersey will support operational health services for some of the nation's largest organizations," said Andrew Morton, CEO of Bloom. "We're focused on occupational health-tech for our clients. However, we continue to see rising demand for testing services due to variants in the ongoing pandemic and testing mandates. With the opening of facilities that cover major centers like New York, we have the ability to meet high-volume testing demands while we scale up our occupational health clients. With locations in key cities, Bloom is well-positioned to support clients across the U.S., both regionally and on a national scale."

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for healthcare security, diagnostic testing, and occupational health-tech. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models. Bloom offers a system for businesses and organizations that helps engage employees and creates strategies to manage health and safety. Our stable, scalable system is an integrated health-tech platform that securely manages data while delivering comprehensive workplace health and safety outcomes.

For more information: info@bloomhealthpartners.com

On behalf of the board of directors,

Bloom Health Partners Inc.

Andrew Morton, Chief Executive Officer

Forward-Looking Statements

This news release includes forward-looking statements that are subject to risks and uncertainties, including statements regarding the development of new facilitates in the United States. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/109223

News Provided by Newsfile via QuoteMedia

BLMH:CNX
Bloom Health Partners

Bloom Health Partners


Keep reading...Show less
Bloom Health Partners Launches $2 Million Non-Brokered Private Placement

Bloom Health Partners Launches $2 Million Non-Brokered Private Placement

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces that it has engaged Ascenta Finance Corp. ("Ascenta") to lead a non-brokered private placement offering (the "Offering") of units (the "Units") at $0.20 per Unit for gross proceeds of up to $2,000,000. The Units are comprised of (i) one (1) common share in the capital of the Company ("Common Shares"); and (ii) one-half (12) transferable common share purchase warrant (each whole warrant, a "Warrant" and collectively, the "Warrants"). Each whole Warrant shall entitle the holder thereof to acquire one (1) additional Common Share (each, a "Warrant Share") in the capital of the Company at a price of $0.30 per Warrant Share until the date that is twelve (12) months from the Closing Date, as defined herein. The net proceeds of the Offering will be used by the Company for ongoing working capital and corporate development.

The Common Shares and the Warrants will be subject to a statutory four month hold period under applicable securities laws and the certificates evidencing the Common Shares and the Warrants will bear a legend to that effect. Closing of the Offering is expected to occur on or about June 22, 2022 or such other date as the Company may determine (the "Closing Date"), and is subject to certain conditions, including but not limited to, the receipt of all necessary regulatory and stock exchange approvals, including the approval of the Canadian Securities Exchange.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Reports Profitable Fiscal Q2 2022 with $11.1 Million in Revenue

Bloom Health Partners Reports Profitable Fiscal Q2 2022 with $11.1 Million in Revenue

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of operational health and health technology, announces unaudited Fiscal Q2 2022 revenues of CAD $11.1M for the period ended March 31st, 2022, bringing year-to-date revenues to $16.9M for the first half of Fiscal 2022.

Highlights in Fiscal Q2 2022:

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Invited to U.K. MedTech Trade Mission

Bloom Health Partners Invited to U.K. MedTech Trade Mission

British Columbia government selects Bloom, a leader in Workplace Health-Tech, to join event designed to open doors, facilitate partnerships, expand business

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for operational health, announced it has been asked by the British Columbia Ministry of Jobs, Economic Recovery & Innovation to join a government-supported virtual trade mission to the United Kingdom.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Extends Contract with State of Texas for K-12 Schools

Bloom Health Partners Extends Contract with State of Texas for K-12 Schools

Program for K-12 schools for lab-based testing along with supply and management of rapid tests is extended through the 2022-2023 school year in Texas.

 Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company") a global platform for operational health, announces that it has been awarded an extension of its state-wide contract for testing in Texas for K-12 schools to the end of the 2022-2023 school year. Bloom's program with schools in Texas, announced in January, includes both rapid and lab testing that covers the needs of schools as they plan for waves and variants associated with the pandemic. As previously announced, Bloom will conduct PCR testing in the Company's Dallas-based laboratory. Rapid tests will continue to be supplied to schools, with results data managed on Bloom's cloud data platform.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Bloom Health Partners Appoints Seasoned Healthcare Executive as Chief Operations Officer--Rosemary Elliston

Bloom Health Partners Appoints Seasoned Healthcare Executive as Chief Operations Officer--Rosemary Elliston

Clinical, technology and operations leadership veteran with a proven track record brings experience to Bloom's Operational Health and Health-Tech strategy

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a global platform for healthcare security, is pleased to announce the appointment of Rosemary Elliston as Chief Operations Officer (COO).

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
How Do Medical Devices Get Approved?

How Do Medical Devices Get Approved?

Life science investors are familiar with the arduous path new drugs must go through to reach the market. But how do medical devices get approved?

In terms of devices, the same rigorous testing and inspection are required from regulatory agencies. The US Food and Drug Administration (FDA) is the agency tasked with reviewing new devices and making amendments to already approved devices.

More specifically, medical device approval is done through the FDA’s Center for Devices and Radiological Health (CDRH). The CDRH looks after the entire regulation process for companies that manufacture, repackage, relabel and import devices to the US.

Keep reading...Show less

Danaher Announces Appointment of Feroz Dewan to Danaher Board

Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board's Science & Technology Committee. This addition expands the size of Danaher's Board from thirteen to fourteen members.

Mr. Dewan is currently CEO of Arena Holdings Management, a global investment business. From 2003 to 2015, he worked at Tiger Global Management, most recently as Head of Public Equities. Prior to that, Mr. Dewan was a private equity investor at Silver Lake Partners.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Hosts Conference Call for Second-Quarter Earnings

Abbott (NYSE: ABT) will announce its second-quarter 2022 financial results on Wednesday, July 20, 2022 before the market opens.

The announcement will be followed by a live webcast of the earnings conference call at 8 a.m. Central time ( 9 a.m. Eastern), and will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com . An archived edition of the call will be available later that day.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies Completes Definitive Manufacturing Agreement with Infinovo Medical for the GluCurve Pet CGM Hardware

ALR Technologies SG Pte. Ltd ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, announces the completion of a definitive manufacturing agreement with Infinovo Medical Co. Ltd ("Infinovo") to manufacture and supply the Continuous Glucose Monitor ("CGM") hardware that will be utilized as part of the ALRT GluCurve Pet CGM (the "Manufacturing Agreement"). The Manufacturing Agreement gives ALRT the exclusive global rights to distribute the Infinovo CGM hardware for the animal health market, providing long-term production and supply. Subject to the satisfaction of all closing conditions it is expected that initial deliveries of product by Infinovo will be made during Q4 of 2022

"Executing the Manufacturing Agreement with Infinovo marks another major milestone in our path to commercialization and profitability," comments Sidney Chan, Chairman and CEO of ALRT. "Our next targeted milestone is securing distribution for the ALRT GluCurve Pet CGM. We have been working with many of the largest global distributors and pharmaceutical companies in animal health, evaluating different distribution opportunities ranging from joint venture partnerships to sales and distribution agreements. We believe we have narrowed in on the right company and right deal structure to best bring value to our shareholders and to those who care for diabetic pets. We hope to announce the details of this pivotal next step in the near future."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Bloom Health Partners CEO Andrew Morton

Bloom Health Partners CEO Andrew Morton: We're Executing the Plan That We Promised Investors

Bloom Health Partners CEO Andrew Morton: We're Executing The Plan That We Promised Investorsyoutu.be

Keep reading...Show less

Medtronic Board appoints Lidia Fonseca as a new director

Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022 . Ms. Fonseca will serve on the Compensation Committee and Science and Technology Committee of the Board.

"We are thrilled to welcome Lidia to Medtronic's Board of Directors," said Geoff Martha , Medtronic chairman and chief executive officer. "She has an impressive history of developing digital healthcare solutions that deliver powerful insights to improve patients' lives. Her extensive knowledge and expertise will provide the Board with an important dimension and a tremendously valuable perspective as we drive toward our bold ambition to become the global leader in healthcare technology."

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×